Trial · NCT04453345
TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL
NCT04453345, Phase 2, Phase 3, Unknown, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL. Trials, record NCT04453345. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04453345
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL
- NCT number
- NCT04453345
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 42 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- T-LGL Leukemia, Clpd-Nk
- Interventions
- thalidomide + prednisone + methotrexate
- First posted
- 2020-07-01
- Last updated
- 2020-07-01
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response (CR) rate of TPM regimen | From date of TPM treatment until the date of complete response, assessed up to 100 months | Hb\> 120g / L，platelet\> 100×109 / L，ANC \> 1.5×109 / L），ALC\< 4×109 / L，peripheral LGL in normal（\< 0.5×109 / L） |
| Secondary | Overall response (PR) | From date of TPM treatment until the date of at least partial response, assessed up to 100 months | improvement in blood counts (ANC \> 0.5 × 10\^9/L; HGB increased by \>1 g/dL; PLT \> 50 × 10\^9/L), and the absence of required transfusions. |
| Secondary | Progression-free survival (PFS) | From date of TPM treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | the length of time during and after the treatment of LGLL |
| Secondary | Duration of response (DoR) | From date of getting response until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | the time from response to progression/death (P/D) |
| Secondary | overall survival | From date of TPM treatment until the date of death from any cause, assessed up to 180 months | the length of the patients survival time |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04453345
GET https://conductscience.org/api/trials/v1/NCT04453345/registered